- Conditions
- Diffuse Cutaneous Systemic Sclerosis, Scleroderma, dcSSc
- Interventions
- Brentuximab Vedotin, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–47
of 23
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Keloid, Scleroderma, Localized, Acne Keloidalis, Scars, Granuloma Annulare
- Interventions
- UVB Irradiation
- Procedure
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 10 Years to 80 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2009
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Interventions
- Mycophenolate Mofetil
- Drug
- Lead sponsor
- Boston University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Autoimmune Diseases, Sickle Cell Disease, Chronic Graft Versus Host Disease
- Interventions
- Acoustic Radiation Force Impulse (ARFI), Laser Doppler Flowmetry (LDF), Laser Doppler Perfusion Imaging (LDI), Optical Coherence Tomography (OCT), Orthogonal Polarization Spectral Imaging (OPSI), Nail fold video capillaroscopy (NVC)
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Interventions
- IgPro10, Placebo
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 20
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 15 more
- Conditions
- Systemic Sclerosis
- Interventions
- SAR100842, Placebo (for SAR100842)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Washington D.C., District of Columbia • Baltimore, Maryland + 4 more
- Conditions
- Scleroderma, Diffuse
- Interventions
- rapcabtagene autoleucel, rituximab
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 13
- States / cities
- Los Angeles, California • San Francisco, California • San Pablo, California + 10 more
- Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Interventions
- Belumosudil
- Drug
- Lead sponsor
- Kadmon, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 6
- States / cities
- Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 3 more
- Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Interventions
- Placebo, Ianalumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2034
- U.S. locations
- 17
- States / cities
- Mesa, Arizona • Los Angeles, California • Newport Beach, California + 14 more
- Conditions
- Scleroderma
- Interventions
- BMS-986020, Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Stanford, California + 13 more
- Conditions
- Systemic Sclerosis, Scleroderma
- Interventions
- Anifrolumab (blinded), Placebo (blinded), Anifrolumab (unblinded, open label)
- Combination Product · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 26
- States / cities
- Scottsdale, Arizona • Chula Vista, California • Los Angeles, California + 23 more
- Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Interventions
- Patients will be randomized to receive EHP-101 or Placebo
- Drug
- Lead sponsor
- Emerald Health Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Huntington Beach, California • Los Angeles, California + 9 more
- Conditions
- Scleroderma, Systemic Sclerosis
- Interventions
- Divalproex sodium
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Interventions
- FCR001
- Biological
- Lead sponsor
- Talaris Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Systemic Sclerosis, Systemic Sclerosis - Diffuse Cutaneous, Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria
- Interventions
- KYV-101, Standard lymphodepletion regimen
- Biological · Drug
- Lead sponsor
- Kyverna Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Palo Alto, California • Great Neck, New York
- Conditions
- Lupus Nephritis, Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Diffuse Cutaneous Systemic Sclerosis
- Interventions
- zamtocabtagene autoleucel, Cyclophosphamide, Fludarabine
- Biological · Drug
- Lead sponsor
- Miltenyi Biomedicine GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Systemic Sclerosis
- Interventions
- Nemolizumab, Placebo
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Arlington, Texas
- Conditions
- System; Sclerosis, Diffuse Cutaneous Systemic Sclerosis
- Interventions
- Belumosudil (KD025), Placebo
- Drug
- Lead sponsor
- Kadmon, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 20 more
- Conditions
- Scleroderma, Systemic
- Interventions
- Riociguat (Adempas, BAY63-2521), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 7 more
- Conditions
- Systemic Sclerosis (SSc), Scleroderma
- Interventions
- Tibulizumab, Placebo
- Biological · Other
- Lead sponsor
- Zura Bio Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 7
- States / cities
- La Jolla, California • Los Angeles, California • Plantation, Florida + 4 more
- Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Interventions
- Abatacept, Placebo
- Drug
- Lead sponsor
- Dinesh Khanna, MD, MS
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 23
- States / cities
- Los Angeles, California • Redwood City, California • Washington D.C., District of Columbia + 17 more
- Conditions
- Systemic Sclerosis
- Interventions
- SAR156597, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 4
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Cleveland, Ohio + 1 more
- Conditions
- Systemic Sclerosis
- Interventions
- Belimumab, Mycophenolate Mofetil, Placebo Infusion
- Drug · Other
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York